deltatrials
Completed PHASE2 INTERVENTIONAL 3-arm NCT05254002

A Study to Learn How Well the Treatment Combination of Finerenone and Empagliflozin Works and How Safe it is Compared to Each Treatment Alone in Adult Participants With Long-term Kidney Disease (Chronic Kidney Disease) and Type 2 Diabetes (CONFIDENCE)

A Parallel-group Treatment, Phase 2, Double-blind, Three-arm Study to Assess Efficacy and Safety of Finerenone Plus Empagliflozin Compared With Either Finerenone or Empagliflozin Alone in Participants With Chronic Kidney Disease and Type 2 Diabetes.

Sponsor: Bayer

Conditions Chronic Kidney Disease Type 2 Diabetes Mellitus
Interventions Empagliflozin Empagliflozin Placebo Finerenone (BAY94-8862 ) 10 mg Finerenone (BAY94-8862 ) 20 mg Finerenone Placebo
Updated 34 times since 2022 Last updated: Mar 17, 2025 Started: Jun 23, 2022 Primary completion: Mar 14, 2025 Completion: Mar 14, 2025
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE2 trial investigates Chronic Kidney Disease and Type 2 Diabetes Mellitus and is currently completed. Bayer leads this study, which shows 34 recorded versions since 2022 — indicating substantial longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

~Mar 2022 – ~Apr 2022 · 31 days · monthly snapshot~Apr 2022 – ~May 2022 · 30 days · monthly snapshot~May 2022 – ~Jun 2022 · 31 days · monthly snapshot~Jun 2022 – ~Jul 2022 · 30 days · monthly snapshot~Jul 2022 – ~Sep 2022 · 2 months · monthly snapshot~Sep 2022 – ~Nov 2022 · 2 months · monthly snapshot~Nov 2022 – ~Dec 2022 · 30 days · monthly snapshot~Dec 2022 – ~Feb 2023 · 2 months · monthly snapshot~Feb 2023 – ~Apr 2023 · 59 days · monthly snapshot~Apr 2023 – ~May 2023 · 30 days · monthly snapshot~May 2023 – ~Jun 2023 · 31 days · monthly snapshot~Jun 2023 – ~Jul 2023 · 30 days · monthly snapshot~Jul 2023 – ~Aug 2023 · 31 days · monthly snapshot~Aug 2023 – ~Sep 2023 · 31 days · monthly snapshot~Sep 2023 – ~Oct 2023 · 30 days · monthly snapshot~Oct 2023 – ~Nov 2023 · 31 days · monthly snapshot~Nov 2023 – ~Dec 2023 · 30 days · monthly snapshot~Dec 2023 – ~Jan 2024 · 31 days · monthly snapshot~Jan 2024 – ~Mar 2024 · 2 months · monthly snapshot~Mar 2024 – ~Apr 2024 · 31 days · monthly snapshot~Apr 2024 – ~May 2024 · 30 days · monthly snapshot~May 2024 – ~Jun 2024 · 31 days · monthly snapshot~Jun 2024 – ~Jul 2024 · 30 days · monthly snapshot~Jul 2024 – ~Aug 2024 · 31 days · monthly snapshot~Aug 2024 – ~Sep 2024 · 31 days · monthly snapshot~Sep 2024 – ~Oct 2024 · 30 days · monthly snapshot~Oct 2024 – ~Nov 2024 · 31 days · monthly snapshot~Nov 2024 – ~Dec 2024 · 30 days · monthly snapshot~Dec 2024 – ~Jan 2025 · 31 days · monthly snapshot~Jan 2025 – ~Feb 2025 · 31 days · monthly snapshot~Feb 2025 – ~Mar 2025 · 28 days · monthly snapshot~Mar 2025 – ~Apr 2025 · 31 days · monthly snapshot~Apr 2025 – ~Sep 2025 · 5 months · monthly snapshot~Sep 2025 – present · 9 months · monthly snapshot

Change History

34 versions recorded

  1. Sep 2025 — Present [monthly]

    Completed PHASE2

  2. Apr 2025 — Sep 2025 [monthly]

    Completed PHASE2

    Status: Active Not Recruiting → Completed

  3. Mar 2025 — Apr 2025 [monthly]

    Active Not Recruiting PHASE2

  4. Feb 2025 — Mar 2025 [monthly]

    Active Not Recruiting PHASE2

  5. Jan 2025 — Feb 2025 [monthly]

    Active Not Recruiting PHASE2

▶ Show 29 earlier versions

  1. Dec 2024 — Jan 2025 [monthly]

    Active Not Recruiting PHASE2

  2. Nov 2024 — Dec 2024 [monthly]

    Active Not Recruiting PHASE2

  3. Oct 2024 — Nov 2024 [monthly]

    Active Not Recruiting PHASE2

    Status: Recruiting → Active Not Recruiting

  4. Sep 2024 — Oct 2024 [monthly]

    Recruiting PHASE2

  5. Aug 2024 — Sep 2024 [monthly]

    Recruiting PHASE2

  6. Jul 2024 — Aug 2024 [monthly]

    Recruiting PHASE2

  7. Jun 2024 — Jul 2024 [monthly]

    Recruiting PHASE2

  8. May 2024 — Jun 2024 [monthly]

    Recruiting PHASE2

  9. Apr 2024 — May 2024 [monthly]

    Recruiting PHASE2

  10. Mar 2024 — Apr 2024 [monthly]

    Recruiting PHASE2

  11. Jan 2024 — Mar 2024 [monthly]

    Recruiting PHASE2

  12. Dec 2023 — Jan 2024 [monthly]

    Recruiting PHASE2

  13. Nov 2023 — Dec 2023 [monthly]

    Recruiting PHASE2

  14. Oct 2023 — Nov 2023 [monthly]

    Recruiting PHASE2

  15. Sep 2023 — Oct 2023 [monthly]

    Recruiting PHASE2

  16. Aug 2023 — Sep 2023 [monthly]

    Recruiting PHASE2

  17. Jul 2023 — Aug 2023 [monthly]

    Recruiting PHASE2

  18. Jun 2023 — Jul 2023 [monthly]

    Recruiting PHASE2

  19. May 2023 — Jun 2023 [monthly]

    Recruiting PHASE2

  20. Apr 2023 — May 2023 [monthly]

    Recruiting PHASE2

  21. Feb 2023 — Apr 2023 [monthly]

    Recruiting PHASE2

  22. Dec 2022 — Feb 2023 [monthly]

    Recruiting PHASE2

  23. Nov 2022 — Dec 2022 [monthly]

    Recruiting PHASE2

  24. Sep 2022 — Nov 2022 [monthly]

    Recruiting PHASE2

    Status: Not Yet Recruiting → Recruiting

  25. Jul 2022 — Sep 2022 [monthly]

    Not Yet Recruiting PHASE2

  26. Jun 2022 — Jul 2022 [monthly]

    Not Yet Recruiting PHASE2

  27. May 2022 — Jun 2022 [monthly]

    Not Yet Recruiting PHASE2

  28. Apr 2022 — May 2022 [monthly]

    Not Yet Recruiting PHASE2

  29. Mar 2022 — Apr 2022 [monthly]

    Not Yet Recruiting PHASE2

    First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Bayer
Data source: Bayer

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

A Coruña, Spain , Aalst, Belgium , Afula, Israel , Ahmedabad, India , Alcalá de Henares, Spain , Amersfoort, Netherlands , Amsterdam, Netherlands , Anyang-si, South Korea , Apeldoorn, Netherlands , Asheboro, United States and 147 more locations